Stefano Bellentani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8539330/publications.pdf

Version: 2024-02-01

97 papers	14,108 citations	57681 46 h-index	48101 92 g-index
148 all docs	148 docs citations	148 times ranked	16152 citing authors

#	Article	IF	Citations
1	The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology, 2006, 6, 33.	0.8	1,817
2	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016â€“2030. Journal of Hepatology, 2018, 69, 896-904.	1.8	1,157
3	Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology, 2005, 42, 44-52.	3.6	1,118
4	Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy. Annals of Internal Medicine, 2000, 132, 112.	2.0	1,051
5	Epidemiology of Non-Alcoholic Fatty Liver Disease. Digestive Diseases, 2010, 28, 155-161.	0.8	772
6	Prevalence of chronic liver disease in the general population of northern Italy: The dionysos study. Hepatology, 1994, 20, 1442-1449.	3.6	504
7	The epidemiology of nonâ€alcoholic fatty liver disease. Liver International, 2017, 37, 81-84.	1.9	503
8	Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology, 2016, 63, 827-838.	3.6	467
9	Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Digestive and Liver Disease, 2015, 47, 997-1006.	0.4	368
10	From NAFLD in clinical practice to answers from guidelines. Journal of Hepatology, 2013, 59, 859-871.	1.8	304
11	Global epidemiology of nonâ€alcoholic fatty liver disease/nonâ€alcoholic steatohepatitis: What we need in the future. Liver International, 2018, 38, 47-51.	1.9	297
12	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Digestive and Liver Disease, 2017, 49, 471-483.	0.4	254
13	Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Annals of Hepatology, 2009, 8, S4-S8.	0.6	244
14	Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut, 1999, 44, 874-880.	6.1	219
15	The spectrum of liver disease in the general population: lesson from the Dionysos study. Journal of Hepatology, 2001, 35, 531-537.	1.8	213
16	Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology, 2008, 47, 746-754.	3.6	204
17	Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. Digestive and Liver Disease, 2010, 42, 272-282.	0.4	202
18	Incidence and natural course of fatty liver in the general population: The Dionysos study. Hepatology, 2007, 46, 1387-1391.	3.6	192

#	Article	IF	Citations
19	A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterology, 2010, 10, 98.	0.8	188
20	Predictors of non-alcoholic fatty liver disease in obese children. European Journal of Clinical Nutrition, 2007, 61, 877-883.	1.3	165
21	Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut, 1999, 45, 435-441.	6.1	145
22	High prevalence of celiac disease in Italian general population. Digestive Diseases and Sciences, 2001, 46, 1500-1505.	1.1	138
23	Microbiota, NASH, HCC and the potential role of probiotics. Carcinogenesis, 2017, 38, 231-240.	1.3	125
24	Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells. Gastroenterology, 1998, 115, 157-166.	0.6	120
25	Moderate alcohol use and health: A consensus document. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 487-504.	1.1	120
26	The epidemiology of fatty liver. European Journal of Gastroenterology and Hepatology, 2004, 16, 1087-1093.	0.8	116
27	Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence. Nutrients, 2018, 10, 1153.	1.7	115
28	Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Annals of Hepatology, 2009, 8 Suppl 1, S4-8.	0.6	110
29	DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: validation in an open population study. Journal of Hepatology, 2001, 34, 587-592.	1.8	96
30	Familial clustering of Helicobacter pylori infection: population based study Â Commentary: Helicobacter pylori---the story so far. BMJ: British Medical Journal, 1999, 319, 537-541.	2.4	92
31	Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. World Journal of Gastroenterology, 2014, 20, 16831.	1.4	90
32	Effect of tauroursodeoxycholic and ursodeoxycholic acid on ethanol-induced cell injuries in the human Hep G2 cell line. Gastroenterology, 1995, 109, 555-563.	0.6	78
33	Cowâ€™s Milk Consumption and Health: A Health Professionalâ€™s Guide. Journal of the American College of Nutrition, 2019, 38, 197-208.	1.1	77
34	Genetic Determinants of Ethanol-Induced Liver Damage. Molecular Medicine, 2001, 7, 255-262.	1.9	75
35	Natural Course of Chronic HCV and HBV Infection and Role of Alcohol in the General Population: The Dionysos Study. American Journal of Gastroenterology, 2008, 103, 2248-2253.	0.2	75
36	Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. Journal of Hepatology, 2013, 58, 771-777.	1.8	74

#	Article	IF	Citations
37	ASH and NASH. Digestive Diseases, 2011, 29, 202-210.	0.8	72
38	Fatty liver: How frequent is it and why?. Annals of Hepatology, 2004, 3, 63-65.	0.6	70
39	Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with <scp>NAFLD</scp> using the <scp>SAF</scp> score as histological reference. Alimentary Pharmacology and Therapeutics, 2016, 44, 877-889.	1.9	70
40	Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: An open question. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 684-698.	1.1	63
41	A survey of pharmacological and nonpharmacological treatment of functional gastrointestinal disorders. United European Gastroenterology Journal, 2013, 1, 385-393.	1.6	62
42	Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. Journal of Hepatology, 1993, 19, 459-464.	1.8	57
43	A â€œsystems medicineâ€•approach to the study of non-alcoholic fatty liver disease. Digestive and Liver Disease, 2016, 48, 333-342.	0.4	56
44	Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient â€“ death of a dogma from analysis of therapeutic studies?. Expert Review of Gastroenterology and Hepatology, 2011, 5, 279-289.	1.4	55
45	A Simple Score for the Identification of Patients at High Risk of Organic Diseases of the Colon in the Family Doctor Consulting Room. Family Practice, 1990, 7, 307-312.	0.8	51
46	Translational approaches: from fatty liver to non-alcoholic steatohepatitis. World Journal of Gastroenterology, 2014, 20, 9038-49.	1.4	43
47	Effect of ursodeoxycholic acid treatment on alanine aminotransferase and Î³-glutamyltranspeptidase serum levels in patients with hypertransaminasemia. Journal of Hepatology, 1989, 8, 7-12.	1.8	42
48	Interaction of alcohol intake and cofactors on the risk of cirrhosis. Liver International, 2010, 30, 867-870.	1.9	40
49	White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths. Digestive and Liver Disease, 2014, 46, 579-589.	0.4	40
50	Immunomodulating and anti-apoptotic action of ursodeoxycholic acid: where are we and where should we go?. European Journal of Gastroenterology and Hepatology, 2005, 17, 137-140.	0.8	37
51	Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD). Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 353-358.	0.7	35
52	Epidemiology of hepatitis C virus infection in Italy: the slowly unraveling mystery. Microbes and Infection, 2000, 2, 1757-1763.	1.0	34
53	Fatty liver: how frequent is it and why?. Annals of Hepatology, 2004, 3, 63-5.	0.6	34
54	Liver and heart: A new link?. Journal of Hepatology, 2008, 49, 300-302.	1.8	33

#	Article	IF	Citations
55	Is it time to change NAFLD and NASH nomenclature?. The Lancet Gastroenterology and Hepatology, 2017, 2, 547-548.	3.7	32
56	Transport of sulfobromophthalein and taurocholate in the HepG2 cell line in relation to the expression of membrane carrier proteins. Biochemical and Biophysical Research Communications, 1992, 183, 1203-1208.	1.0	30
57	Ethanol-induced increase in cytosolic estrogen receptors in human male liver: A possible explanation for biochemical feminization in chronic liver disease due to alcohol. Hepatology, 1988, 8, 1610-1614.	3.6	28
58	Milk thistle to treat non-alcoholic fatty liver disease: dream or reality?. Expert Review of Gastroenterology and Hepatology, 2013, 7, 677-679.	1.4	25
59	Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study. BMC Gastroenterology, 2018, 18, 177.	0.8	23
60	Chronic Administration of Ursodeoxycholic and Tauroursodeoxycholic Acid Changes Microsomal Membrane Lipid Content and Fatty Acid Composition in Rats. Biochemical and Biophysical Research Communications, 1996, 220, 479-483.	1.0	19
61	Is there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population?. Annals of Hepatology, 2020, 19, 380-387.	0.6	19
62	Sex steroid modulation of the hepatic uptake of organic anions in rat. Journal of Hepatology, 1988, 6, 343-349.	1.8	18
63	Natural history of HBV infection: a 9 years follow up of the dionysos cohort. Journal of Hepatology, 2002, 36, 228.	1.8	15
64	External Validation of Surrogate Indices of Fatty Liver in the General Population: The Bagnacavallo Study. Journal of Clinical Medicine, 2021, 10, 520.	1.0	15
65	Correlation between bromodeoxyuridine labelling and ornithine decarboxylase levels in normal rectal mucosa of patients with colorectal adenoma. Cancer Letters, 1991, 59, 221-224.	3.2	12
66	Risk factors for alcoholic liver disease. Addiction Biology, 2000, 5, 261-268.	1.4	12
67	Accuracy of body mass index in detecting an elevated alanine aminotransferase level in adolescents. Annals of Human Biology, 2004, 31, 570-577.	0.4	12
68	HCV, HBV and Alcohol â€“ the Dionysos Study. Digestive Diseases, 2010, 28, 799-801.	0.8	12
69	Pegylated interferon Î± plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency. Digestive and Liver Disease, 2014, 46, 826-832.	0.4	12
70	Nonalcoholic fatty liver disease burden â€“ Switzerland 2018â€“2030. Swiss Medical Weekly, 2019, 149, w20152.	0.8	12
71	Mechanisms of liver adaptation to prolonged selective biliary obstruction (SBO) in the rat. Journal of Hepatology, 1985, 1, 525-535.	1.8	11
72	BT-Paba test in the diagnosis of pancreatic exocrine insufficiency in cystic fibrosis: urinary and serum determinations compared. European Journal of Pediatrics, 1984, 143, 145-148.	1.3	9

#	Article	IF	Citations
73	The effect of etofibrate on cholesterol and bile acid metabolism in the hamster. Pharmacological Research, 1989, 21, 567-576.	3.1	9
74	Body mass index is a good predictor of an elevated alanine transaminase level in the general population: hints from the Dionysos study. Digestive and Liver Disease, 2003, 35, 648-652.	0.4	9
75	Study of the long-term effects of selective biliary obstruction (SBO). Research in Experimental Medicine, 1981, 178, 229-235.	0.7	8
76	The management of patients with new onset of upper gastro-intestinal symptoms in primary care. Digestive and Liver Disease, 2010, 42, 860-864.	0.4	8
77	PDX-1 mRNA expression in endoscopic ultrasound-guided fine needle cytoaspirate: Perspectives in the diagnosis of pancreatic cancer. Digestive and Liver Disease, 2015, 47, 138-143.	0.4	8
78	Fulminant Hepatitis in a Patient with Hepatocellular Carcinoma Related to Nonalcoholic Steatohepatitis Treated with Sorafenib. Tumori, 2015, 101, e46-e48.	0.6	7
79	Alcohol-induced liver disease: From molecular damage to treatment. Revista Medica De Chile, 2002, 130, 681-90.	0.1	7
80	Editorial: The North-to-South Gradient of Hepatitis C Virus Infection. Scandinavian Journal of Gastroenterology, 2003, 38, 805-806.	0.6	6
81	Bile-Acid Binding to Isolated Rat Liver Plasma Membranes. Failure to Find a Specific Binding Site. Hoppe-Seyler's Zeitschrift FÃ¼r Physiologische Chemie, 1984, 365, 357-364.	1.7	4
82	Role and nature of plasma membrane carrier proteins in the hepatic transport of organic anions. Journal of Gastroenterology and Hepatology (Australia), 1989, 4, 195-205.	1.4	4
83	Clinical update on non-alcoholic fatty liver disease and steatohepatitis. Annals of Hepatology, 2008, 7, 157-60.	0.6	4
84	Nonalcoholic Fatty Liver Disease: A Wide Spectrum Disease. , 2020, , 273-284.		3
85	The role of calcium precipitation in the sulfoglycolithocholate-induced cholestasis of the bile fistula hamster. Journal of Hepatology, 1990, 10, 356-363.	1.8	2
86	Natural history of nonalcoholic steatohepatitisâ€“associated hepatocellular carcinoma. Clinical Liver Disease, 2016, 8, 105-107.	1.0	2
87	Missed treatment in an Italian HBV infected patients cohort: HBV RER. Digestive and Liver Disease, 2016, 48, 1346-1350.	0.4	2
88	Two drinks per day does not take your fatty liver away. Hepatology, 2018, 67, 2072-2073.	3.6	2
89	Is there an effective therapy available for non-alcoholic fatty liver disease?. F1000 Medicine Reports, 2009, 1, .	2.9	2
90	Serum PABA test in chronic pancreatitis.. Gut, 1985, 26, 537-538.	6.1	1

#	Article	IF	Citations
91	Estrogens keep alive the hepatocyte memory. Hepatology, 1988, 8, 693-695.	3.6	1
92	Twenty years of modelling NPM-ALK-induced lymphomagenesis. Frontiers in Bioscience - Scholar, 2015, 7, 236-247.	0.8	1
93	Alcohol and Nutrition as Risk Factors for Chronic Liver Disease. , 2013, , 497-506.		1
94	Serum ferritin and liver inflammation: which come first? Chicken or egg?. Annals of Hepatology, 2014, 13, 315-316.	0.6	0
95	Viewpoint: â€œAlcohol Consumption in Late Adolescence is Associated With an Increased Risk of Severe Liver Disease Later in Lifeâ€• Annals of Hepatology, 2018, 17, 343-344.	0.6	0
96	Histological primary biliary cholangitis changes in patients with positive serology and normal alkaline phosphatase. Journal of Hepatology, 2020, 73, S461-S462.	1.8	0
97	Alcohol and Nutrition as Risk Factors for Chronic Liver Disease. , 2003, , 73-85.		0